Salk team reveals never-before-seen antibody binding, informing both liver cancer and antibody design
Some molecules are so elusive that scientists require a unique set of tools to capture their structure. That’s precisely how a multi-institutional research team led by Salk scientist Tony Hunter and Salk postdoctoral fellow Rajasree Kalagiri, featured in this issue’s “Next Gen,” defined how antibodies recognize a compound called phosphohistidine—an unstable molecule that’s implicated in certain cancers, such as liver and breast cancer and neuroblastoma. These insights could help researchers understand the molecule’s role in cancer pathways and also enable the design of more efficient antibodies in the future.
Featured Stories
The aging puzzle comes togetherAging is a complex puzzle, but by applying a collaborative, multidisciplinary approach, Salk scientists are putting its many pieces together.
Dmitry Lyumkis – A passion for problem solvingAssistant Professor Dmitry Lyumkis discusses what he loves about data and the scientific process, and which places inspire him outside the lab.
Pamela Maher – Seeking treatments for Alzheimer’s diseaseFrom having a large garden to investigating compounds that plants make, Staff Scientist Pam Maher talks about how plants inspire her to find treatments for Alzheimer’s disease.
Rajasree Kalagiri – Bound to phosphohistidineRajasree Kalagiri shares the serendipitous steps along her journey of scientific discovery from southern India to Southern California.
